News
Are RSV vaccines going to be the next blockbuster vaccine to be developed?
The below graph shows that the rate of RSV-associated hospitalizations has increased significantly after the COVID pandemic (2020-2021 season).
In the 2022-2023 season, the current estimate for RSV-associated hospitalization stood at 18 per 100k people in the US. However, this is just the start of the
3 Top Biotech News Of The Week (22 Oct 2022) - Oculis, LLY, AKUS, JAZZ, ZYME
1) Another ophthalmology acquisition: Oculis. SA and European Biotech Acquisition Corp. announce business combination agreement
The resultant company, Oculis Holding SA will work to accelerate the development of Oculis’s differentiated ophthalmology pipeline therapeutics for diabetic macular edema, dry eye disease, and neuro-retina indications such as glaucoma.
Oculis’ pipeline
A look at Nimbus & Eli Lilly's AMPK Collaboration, Regeneron and Sanofi's Dupixent EOE approval and Merck's Sotatercept for PAH
1) Eli Lilly (NYSE: LLY) enters into collaboration with Nimbus to develop therapeutics for metabolic diseases
Eli Lilly and Nimbus enter into a collaboration to develop therapeutics for metabolic diseases.
The two companies will collaborate on the development of novel targeted therapies designed to activate a specific isoform of AMPK
3 Top Biotech News Of The Week (8 October 22) - BMS, AUTL, DNA, Svante Pääbo discovery
1) Bristol Myers Squibb (BMS) enters into 2 licensing deals with SynethX and Autolus Therapeutics (AUTL)
Bristol Myers Squibb (NYSE: BMS) entered into 2 licensing deals with SynethX Inc and Autolus Therapeutics (NASDAQ: AUTL).
The first deal is with SynethX which will focus on discovering molecular glue degraders. Synethx has
3 Top Biotech News Of The Week (1 October 22)
1) Eisai and Biogen Report Positive Phase III Data for Anti-Amyloid Alzheimer's Drug
Eisai and Biogen announced that the duo’s Alzheimer's drug, Lecanemab, slowed the rate of cognitive decline for early Alzheimer’s participants in the phase 3 clinical trial by 27% compared to
3 Top Biotech News Of The Week (10 September 22)
1. Iveric plans FDA submission of data for geographic atrophy eye-drug following study success
Iveric Bio announced positive phase 3 topline data from Zimura for geographical atrophy (GA). Zimura is a novel investigational complement C5 inhibitor.
Overactivity of the complement system and the C5 protein are suspected to play